Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/365—Lactones
  • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
  • A61K31/37—Coumarins, e.g. psoralen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
  • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
  • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
  • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
  • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
  • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/10—Type of nucleic acid
  • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2320/00—Applications; Uses
  • C12N2320/30—Special therapeutic applications
  • C12N2320/32—Special delivery means, e.g. tissue-specific

Definitions

• the present invention provides a novel delivery vector for nucleic acids such as plasmid DNAs, antisense oligonucleotides, small interfering RNAs (siRNAs), small hairpin RNAs (shRNAs), microRNA and messenger RNA to improve their use for the prevention or treatment of various diseases and / or disorders. Additionally, the present invention provides a novel treatment for cancer, such as breast cancer.
• Nucleic acids have emerged as promising therapeutic candidates for cancer treatment, including immunotherapy.
• Nucleic acids are a diverse class of DNA or RNA such as plasmids, mRNA, ASO, siRNA, miRNA, small-activating RNA (saRNA), aptamers, gene-editing gRNA, as well as immunomodulatory DNA/RNA.
• Nucleic acid therapeutics have versatile functionalities ranging from altering (up- or down- regulating) gene expression, to modulating immune responses. The high specificity, versatile functionality, reproducible batch-to-batch manufacture, and tuneable immunogenicity of nucleic acids make them good candidates for cancer immunotherapy.
• RNAs small interfering RNAs
• ONPATTROTM drug patisiran
• hATTR hereditary transthyretin-mediated amyloidosis
• GIVALAARITM givosiran
• GIVALAARITM givosiran
• Other siRNA therapies are also in development and in clinical evaluation.
• siRNA has significant potential for treatment, challenges remain because introducing either naked or encapsulated nucleic acids into a carrier for combination with biological fluids encounters many physiological barriers that alter the cellular biodistribution and intracellular bioavailability of the siRNA.
• unmodified DNA and RNA rapidly degrade in biological fluids by extra- and intracellular enzymes before they can reach the surface of the target cells. This influences their activity and interaction with the cells, compromising the therapeutic outcomes of nucleic acids.
• nucleic acids have very limited cellular uptake because of their hydrophilic nature and high molecular weight. A small fraction that can be taken up by the cells is usually internalized into vesicles (i.e., endosomes), which convert later into lysosomes.
• vectors should be small enough to be taken up by cells and possess either targeting moieties or an excess positive charge to facilitate cell binding and subsequent uptake.
• a viral vector can achieve a higher degree of transport efficacy, concerns remain regarding the safety and limitations on scalability of such vectors. Accordingly, non-viral vectors are preferred despite the lower therapeutic effect.
• Incorporation of fusogenic lipids or peptides or membrane destabilizing polymers can be employed to facilitate escape of the genetic material from the endosomes/lysosomes into the cytoplasm. Tagging with a nuclear homing sequence to increase expression efficiency can also be utilized when using pDNA.
• these complexes should have intermediate stability; be robust enough to carry the nucleic acids to the target site, but dissociate from them at their targeted subcellular compartment/organelle.
• intracellular delivery to the target site requires the presence of a delivery vector.
• Inclusion of a delivery vector in the therapeutic composition can limit the therapeutic potential of the active RNA agent.
• non-viral vectors will be synthetic particles together with perpetually charged quaternary ammonium-based cationic lipids (PCCLs) or cationic polymers (PCCPs) and produce siRNA complexes followed by transfection, but generally require pH- responsive lipid comprising protonable amine groups to reduce toxicity.
• PCCLs quaternary ammonium-based cationic lipids
• PCCPs cationic polymers
• pH- responsive lipid comprising protonable amine groups to reduce toxicity.
• tri- phenylphosphonium (TPP) tethered polymer-based delivery systems are gaining prominence as non-toxic alternatives to the ammonium-based systems because of their superior safety and transfection ability.
• TPP-anchored molecules due to the amphiphilic character and delocalized positive charge, exhibit enhanced biocompatibility, membrane fusion, cellular uptake and also mitochondrial targeting.
• the present invention provides a novel nucleic acid delivery method based on a phosphonium amphiphile.
• the phosphonium amphiphile described has the ability to form aggregates and subsequently deliver nucleic acids such as siRNA to the target cells by forming phosphonium-siRNA complexes.
• An exemplary phosphonium amphiphile according to the present invention is triphenylphosphoium cation (TPP+) coupled esculetin (herein referenced as “Mito-Esculetin” or “Mito-Esc”, which terms are used herein interchangeably) .
• Mito-Esc The molecular structure of Mito-Esc consists of a lipophilic TPP cation linked to a hydrophilic 6,7-dihydroxy coumarin molecule through 8-carbon aliphatic chain.
• Mito-Esc is an amphiphilic molecule comprised of architecture possessing opposing faces, hydrophobic and hydrophilic groups, within the same molecule.
• mitochondria-targeted esculetin greatly alleviates atherosclerotic disease progression by mitigating oxidant-induced endothelial dysfunction.
• Mito-Esc while improving the oxidant- mediated cellular abnormalities, causes preferential breast cancer cell death.
• the present invention exploited the hydrophobic property of the TPP cation and the hydrophilic property of 6,7-dihydroxy coumarin to form self-assembled nanoparticles and serve as an efficient nucleic acid delivery vector, such as a siRNA delivery vector.
• the negatively charged therapeutic agent may be a therapeutic agent or a diagnostic agent.
• the negatively charged agent can be a nucleic acid, for example plasmid DNAs, antisense oligonucleotides, small interfering RNAs (siRNAs), small hairpin RNAs (shRNAs), micro RNA and messenger RNA (mRNA). More specifically a siRNA or mRNA, which is targeted at treating or diagnosing a specific disease or disorder.
• the present inventors have found that the complex of the 6,7-dihydroxy coumarin phosphonium amphiphile together with a negatively charged agent self-assembles into a nanoparticle or non-viral vector.
• the present invention provides a method of delivery of a negatively charged agent to a target cell, and in particular delivery of the agent across the plasma membrane.
• the 6,7- dihydroxy coumarin phosphonium amphiphile complex and nanoparticle is a compound of Formula F
• Z is a negatively charged agent or a negatively charged counterion selected from a halide, mesylate, tosylate, citrate, tartrate, malate, acetate and trifluoroacetate;
• R is hydrogen, a substituted alkyl, a substituted aryl or a substituted heteroatom
• Ri is an aryl, a cycloalkyl or a heteroaryl
• X is a Ci to C30 carbon chain including one or more double or triple bonds, unsubstituted or substituted with alkyl, alkenyl or alkynyl side chains, or
• X is a Ce to C10 carbon chain
• R is hydrogen
• 6,7-dihydroxy coumarin phosphonium amphiphile is a triphenylphosphonium cation covalently coupled to a 6,7- dihydroxy coumarin moiety. More specifically, the complex and nanoparticle is a compound of Formula II: wherein,
• X is a Ci to C30 carbon chain, preferably a Ce to C10 carbon chain
• Z is a negatively charged agent or a halide; and R is hydrogen.
• the complex and nanoparticle of compound of formula I or II is a compound of Formula III: Formula III
• Z is a negatively charged agent or a halide.
• the present invention therefore also provides the 6,7-dihydroxy coumarin phosphonium amphiphile or pharmaceutically acceptable salt thereof for use in the treatment of cancer, in particular breast cancer and in a method of treatment of cancer, said method comprising administering the 6,7-dihydroxy coumarin phosphonium amphiphile or pharmaceutically acceptable salt thereof to a patient in need thereof.
• FIG. 1 Mito-Esc dose- and time-dependently induces breast cancer cell death without affecting normal cell viability.
• A MDA-MB-231 breast cancer cells were treated with various concentrations of Mito-Esc (1.25-7.5 mM). Cell viability was measured by trypan blue dye exclusion assay at 24 h and 48 h.
• B Same as A, except that cells were treated with parent Esc (5-50 mM).
• C Same as A, except that MCF10A (normal mammary epithelial) cells were treated with Mito-Esc (5-50 pM).
• * Significantly different from control (P ⁇ 0.05). ns; not significantly different from control).
• Figure 2 (A) DLS: Size distribution of Mito-Esc nanoparticles; (B) SEM image of Mito- Esc nanoparticles: Scanning electron micrographs of Mito-Esc nanoparticle (Scale bar 100 nm); (C) TEM image of Mito-ESC nanoparticle: Transmission electron micrographs (TEM) of Mito-Esc nanoparticles, samples were negatively stained with ammonium molyb-date (Scale bar 200 nm).
• TEM Transmission electron micrographs
• FIG. 3 MitoEsc administration regress breast cancer progression SCID mice model: (A) Representative tumors from each group are shown as indicated; (B) graph depicts mean tumor volume ⁇ SEM in mm 3 on the day of termination; (C) graph shows tumor weights; (D) Mean Necrotic index was calculated in three individual tumor sections. Data represents Mean ⁇ SE of four animals.
• FIG. 4 Mito-Esc/siMnSOD complex by depleting MnSOD levels exacerbates Mito-Esc- induced breast cancer cell death.
• A MDA-MB-231 cells were incubated either with Mito- Esc/siMnSOD (40 nM) complex or with lipofectamine-2000/siMnSOD complex for 48 h and cell viability was measured by trypan blue dye exclusion assay.
• B MDA-MB-231 cells were transfected with siMnSOD (40 nM) with indicated delivery systems for 48 h and MnSOD protein levels were measured by immunoblotting. Parenthesis indicates the relative expression of MnSOD normalized to GAPDH (loading control). (*, Significantly different from control (P ⁇ 0.05). ns; not significantly different from control.).
• FIG. 5 Detection of intracellular delivery of Cy-5 siRNA by Mito-Esc using confocal imaging.
• MDA-MB-231 cells were transfected with Cy-5 labelled siRNA (40 nM) with indicated delivery systems for 24 h. Transfection efficacy was evaluated using Confocal Microscopy. Cy-5 fluorescence in the cytosol is shown in blue color (Scale bar 10X).
• FIG. 6 Comparison of intracellular delivery of Cy-5 siRNA using confocal imaging. MCF-IOA cells were transfected with Cy-5 labelled siRNA using different delivery mechanisms. Transfection efficacy was evaluated using Confocal Microscopy. Cy-5 fluorescence in the cytosol is shown in blue.
• alkyl in the present invention is meant a straight or branched hydrocarbon radical and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, Sec -butyl, isobutyl, tert-butyl, n-pentyl, iso-pentyl, n-hexyl, n-octyl and the like.
• Alkenyl 1 means straight and branched hydrocarbon radicals and at least one double bond and includes, but is not limited to, ethenyl, 3-butenl-yl, 2-ethenylbutyl, 3-hexen-l-yl, and the like.
• Alkynyf means straight and branched hydrocarbon radicals and at least one triple bond and includes, but is not limited to, ethynyl, 3-butyn 1-yl, propynyl, 2-butyn-l-yl, 3- pentyn-l-yl, and the like.
• aryl 1 is meant an aromatic carbocyclic group having a single ring (e.g., phenyl), multiple rings (e.g., biphenyl), or multiple condensed rings in which at least one is aromatic, (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl, anthryl, or phenanthryl), which can be mono-, di-, or trisubstituted with, e.g., halogen, lower alkyl, lower alkoxy, lower alkylthio, trifluoromethyl, lower acyloxy, aryl, heteroaryl, and hydroxy.
• a preferred aryl is phenyl.
• Heteroatom means an atom of any element other than carbon or hydrogen. Preferably, heteroatoms are nitrogen, oxygen, and sulfur.
• Cycloalkyl means a monocyclic or polycyclic hydrocarbyl group having from 3 to 8 carbon atoms, for instance, cyclopropyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclobutyl, adamantyl, norpinanyl, decalinyl, norbomyl, cyclohexyl, and cyclopentyl.
• halide 1 in the present invention is meant fluoride, bromide, chloride, and iodide.
• heteroaryl is meant one or more aromatic ring systems of 5-, 6-, or 7-membered rings containing at least one and up to four heteroatoms selected from nitrogen, oxygen, or sulfur.
• heteroaryl groups include, for example, thienyl, furanyl, thiazolyl, triazolyl, imidazolyl, (is)oxazolyl, oxadiazolyl, tetrazolyl, pyridyl, thiadiazolyl, oxadiazolyl, oxathiadiazolyl, thiatriazolyl, pyrimidinyl, (iso) quinolinyl, napthyridinyl, phthalimidyl, benzimidazolyl, and benzoxazolyl.
• “Therapeutically effective amount” as used herein refers to the amount of a therapeutic agent that is effective to alleviate the target disease or disorder.
• Patient refers to any human or nonhuman animal (e.g., primates, sheep, dogs, cats, horses, cows, chickens, amphibians, reptiles and the like).
• Treatment refers to cure the disease and/or disorder as rapidly as possible and to prevent the progression to severe disease.
• the present invention is based on the surprising finding that a 6,7-dihydroxy coumarin phosphonium amphiphile can self-aggregate with a negatively charged agent, to form a vector or nanoparticle which is particularly suitable to facilitate the delivery of the agent into a target cell (for example a cancer cell).
• the negatively charged agent may be a therapeutic agent or a diagnostic agent.
• the 6,7-dihydroxy coumarin phosphonium amphiphile is a triphenylphosphonium cation covalently coupled to a 6,7- dihydroxy coumarin moiety.
• a preferred 6,7-dihydroxy coumarin phosphonium amphiphile is octyl tagged esculetin (Mito-Esculetin).
• 6,7-dihydroxy coumarin phosphonium amphiphile is useful for the treatment and diagnosis of cancer, in particular breast cancer, cervical cancer, lung cancer and liver cancer. More particularly, in breast cancer such as triple-negative breast cancer and ER+ve breast cancer.
• the present invention provides complex of a 6,7-dihydroxy coumarin phosphonium amphiphile together with a negatively charged agent.
• the negatively charged agent can be a nucleic acid, for example, a plasmid DNAs, antisense oligonucleotides, small interfering RNAs (siRNAs), small hairpin RNAs (shRNAs), microRNA and messenger RNA (mRNA).
• siRNAs small interfering RNAs
• shRNAs small hairpin RNAs
• mRNA messenger RNA
• the negatively charged agent may be a therapeutic agent or a diagnostic agent.
• the therapeutic agent is intended for delivery to the cytoplasm of a target cell, thereby exerting its intended therapeutic effect within the cytoplasm of the target cell.
• the therapeutic agent will be negatively charged anti-cancer agents, a siRNA or mRNA.
• the siRNA may be effective for the treatment or diagnosis of any disease or disorder, for example the treatment or diagnosis of cancer, peripheral nerve disease, acute hepatic porphyria and others.
• the siRNA can be used to treat breast cancer, cervical cancer, lung cancer and liver cancer. More particularly, breast cancers such as triple-negative breast cancer and ER+ve breast cancer.
• the therapeutic agent can be an RNA vaccine, for example an RNA vaccine against a virus, for example coronavirus.
• the 6,7-dihydroxy coumarin phosphonium amphiphile complex is a compound of Formula I wherein, Z is a negatively charged agent or a negatively charged counterion selected from a halide, mesylate, tosylate, citrate, tartrate, malate, acetate and trifluoroacetate;
• R is hydrogen, a substituted alkyl, a substituted aryl or a substituted heteroatom
• Ri is an aryl, a cycloalkyl or a heteroaryl
• X is a Ci to C30 carbon chain including one or more double or triple bonds, unsubstituted or substituted with alkyl, alkenyl or alkynyl side chains, or -(CH 2 )p-R2-(CH 2 )n-, or -(CH 2 ) 2 -R 2 -(CH 2 ) 2 -R 2 -(CH 2 )m-; wherein, p is 2 or 3, n is an integer from 3 to 6, and m is an integer from 2 to 4; and
• 3 ⁇ 4 is O, NH or S.
• the 6,7-dihydroxy coumarin phosphonium amphiphile can be a triphenylphosphonium cation covalently coupled to a 6,7- dihydroxy coumarin moiety. More specifically, the 6,7-dihydroxy coumarin phosphonium amphiphile complex is a compound of Formula II : wherein,
• X is a Ci to C30 carbon chain, preferably a Ce to C10 carbon chain
• Z is a negatively charged agent or a halide
• R is hydrogen, one or more substituted alkyl, one or more substituted aryl or one or more substituted heteroatom.
• R is hydrogen.
• the negatively charged agent may be a therapeutic agent or a diagnostic agent.
• Z is a negatively charged therapeutic agent.
• X is a Cl to C30 carbon chain including one or more double or triple bonds, unsubstituted or substituted with alkyl, alkenyl or alkynyl side chains.
• X is an octylene group.
• the 6,7-dihydroxy coumarin phosphonium amphiphile is Mito-Esculetin. More specifically, the 6,7-dihydroxy coumarin phosphonium amphiphile complex is a compound of formula Ill: Formula III
• Z is a negatively charged agent or a halide.
• US9580452 describes a method of synthesis of compounds according to Formula I, II and III, particular the synthesis of Mito-Esculetin.
• the complex comprises Mito-Esculetin in combination with an RNA therapeutic agent for example a siRNA.
• the complexes of the invention can self-assemble into nanoparticles or non-viral vectors. These nanoparticles are particularly suitable for delivery of a therapeutic agent or diagnostic agent to a patient, and in particular are suitable for delivery of a negatively charged therapeutic agent into the cytoplasm of a target cell.
• the present invention provides, in addition to the complex described above, a nanoparticle comprising a 6,7-dihydroxy coumarin phosphonium amphiphile.
• the nanoparticle preferably comprises a negatively charged agent.
• the negatively charged agent can be a nucleic acid, for example, plasmid DNAs, antisense oligonucleotides, small interfering RNAs (siRNAs), small hairpin RNAs (shRNAs), microRNA and messenger RNA (mRNA). However, all that is required is that the agent possesses a negative charge, so that it will associate with the 6,7-dihydroxy coumarin phosphonium amphiphile.
• the negatively charged agent may be a therapeutic agent or a diagnostic agent.
• the therapeutic agent is intended for delivery to the cytoplasm of a target cell, thereby exerting its intended therapeutic effect within the cytoplasm of the target cell.
• the therapeutic agent will be negatively charged anti-cancer agents, a siRNA or mRNA.
• the siRNA may be effective for the treatment or diagnosis of any disease or disorder, for example the treatment or diagnosis of cancer, peripheral nerve disease, acute hepatic porphyria and others.
• the siRNA can be used to treat breast cancer, cervical cancer, lung cancer and liver cancer. More particularly, breast cancers such as triple-negative breast cancer and ER+ve breast cancer.
• the therapeutic agent can be an RNA vaccine, for example an RNA vaccine against a vims, for example coronavirus.
• the agent is a siRNA.
• the siRNA can be targeted to treating or diagnosing any specific disease or disorder.
• the nanoparticle can have a size of 100 to 200 nm, for example from 150 to 180 nm, preferably around 160-170nm.
• the nanoparticle can have a surface charge of 30 to 40 mV.
• the nanoparticle can have a surface charge of 30 mV or greater.
• the present invention further provides a composition comprising a nanoparticle or complex according to the present invention.
• the composition is an aqueous solution or suspension.
• composition according to the invention is in a pharmaceutically acceptable form.
• the pharmaceutical composition is formulated for oral or parenteral administration.
• the pharmaceutical composition is administered as an oral dosage form.
• the oral dosage form is in the form of tablet, capsule, dispersible tablets, sachets, sprinkles, liquids, solution, suspension, emulsion and the like. If the oral dosage form is a tablet, the tablet can be of any suitable shape such as round, spherical, or oval. The tablet may have a monolithic or a multi-layered structure.
• the pharmaceutical composition of the present invention can be obtained by conventional approaches using conventional pharmaceutically acceptable excipients well known in the art.
• Examples of pharmaceutically acceptable excipients suitable for tablet preparation include, but are not limited to, diluents (e.g., calcium phosphate- dibasic, calcium carbonate, lactose, glucose, microcrystalline cellulose, cellulose powdered, silicified microcrystalline cellulose, calcium silicate, starch, starch pregelatinized, or polyols such as mannitol, sorbitol, xylitol, maltitol, and sucrose), binders (e.g., starch, pregelatinized starch, carboxymethyl cellulose, sodium cellulose, microcrystalline cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, crospovidone, or combinations thereof), disintegrants (e.g., cross- linked cellulose, cross-linked-polyvinylpyrrolidone (crosspovidone), sodium starch glycolate, polyvinylpyrrolidone (polyvidone, povidone),
• the parenteral administration can be formulated as a solution, suspension, emulsion, particle, powder, or lyophibzed powder in association, or separately provided, with a pharmaceutically acceptable parenteral vehicle.
• a pharmaceutically acceptable parenteral vehicle examples include water, saline, Ringer's solution, dextrose solution, and about 1-10% human serum albumin. Liposomes and non-aqueous vehicles, such as fixed oils, can also be used.
• the vehicle or lyophilized powder can contain additives that maintain isotonicity (e.g., sodium chloride, mannitol) and chemical stability (e.g., buffers and preservatives).
• the formulation is sterilized by known or suitable techniques.
• parenteral formulation may comprise a common excipient that includes, but not limited to, sterile water or saline, polyalkylene glycols, such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes and the like.
• Aqueous or oily suspensions for injection can be prepared by using an appropriate emulsifier or humidifier and a suspending agent, according to known methods.
• Parenteral route of administration includes, but is not limited to, subcutaneous route, intramuscular route, intravenous route, intrathecal route or intraperitoneal.
• formulations of the present invention can be prepared by a process known or otherwise described in the prior art, for example the process disclosed in Remington's Pharmaceutical Sciences.
• the complex or nanoparticle of the present invention can be useful in the treatment or diagnosis of cancer.
• cancer for example, for the treatment of breast cancer, cervical cancer, lung cancer and liver cancer. More particularly, in breast cancers such as triple-negative breast cancer and ER+ve breast cancer.
• the present invention further provides a method of delivering a negatively charged agent, wherein said agent is complexed to a 6,7-dihydroxy coumarin phosphonium amphiphile.
• the complex of the agent and 6,7-dihydroxy coumarin phosphonium amphiphile is in the form of a nanoparticle, as described above.
• the negatively charged agent may be a therapeutic agent or a diagnostic agent.
• the present invention provides a method of delivering a negatively charged therapeutic agent, wherein said agent is complexed to a 6,7-dihydroxy coumarin phosphonium amphiphile. More preferably, the complex of the therapeutic agent and 6,7-dihydroxy coumarin phosphonium amphiphile is in the form of a nanoparticle.
• the present invention further provides a method of intracellular delivery of a negatively charged agent, said method comprising administering an effective amount of said agent complexed to a 6,7-dihydroxy coumarin phosphonium amphiphile.
• the complex of the agent and 6,7-dihydroxy coumarin phosphonium amphiphile is in the form of a nanoparticle, as described above.
• the negatively charged agent may be a therapeutic agent or a diagnostic agent.
• the invention provides a method of intracellular delivery of a negatively charged therapeutic agent, said method comprising administering an effective amount of said therapeutic agent complexed to a 6,7-dihydroxy coumarin phosphonium amphiphile. More preferably, the complex is in the form of a nanoparticle.
• the negatively charged agent is complexed to a 6,7- dihydroxy coumarin phosphonium amphiphile, and said complex can be further assembled into the form of a nanoparticle or non-viral vector.
• the negatively charged agent can be a nucleic acid, for example, plasmid DNAs, antisense oligonucleotides, small interfering RNAs (siRNAs), small hairpin RNAs (shRNAs), microRNA and messenger RNA (mRNA).
• siRNAs small interfering RNAs
• shRNAs small hairpin RNAs
• mRNA messenger RNA
• the negatively charged agent may be a therapeutic agent or a diagnostic agent.
• the therapeutic agent is intended for delivery to the cytoplasm of a target cell, thereby exerting its intended therapeutic effect within the cytoplasm of the target cell.
• the therapeutic agent will be negatively charged anti-cancer agent, a siRNA or mRNA.
• the siRNA may be effective for the treatment or diagnosis of any disease or disorder, for example, the treatment or diagnosis of cancer, peripheral nerve disease, acute hepatic porphyria and others.
• the siRNA can be used to treat breast cancer, cervical cancer, lung cancer and liver cancer. More particularly, in breast cancers such as triple-negative breast cancer and ER+ve breast cancer.
• the therapeutic agent can be an RNA vaccine, for example an RNA vaccine against a virus, for example coronavirus.
• the agent is a siRNA.
• the siRNA can be targeted at treating or diagnosing any specific disease or disorder.
• the siRNA can be effective at targeting cancer to trigger their specific cell death and / or to prevent cell growth and division of such cells.
• the siRNA can be specifically targeted to breast cancer cells.
• the present invention also provides a method of treating or ameliorating the progression of cancer, wherein said method comprises administration of a pharmaceutically acceptable composition comprising the nanoparticle of 6,7-dihydroxy coumarin phosphonium amphiphile and negatively charged therapeutic agent to the patient.
• said 6,7-dihydroxy coumarin phosphonium amphiphile is Mito- Esc and said therapeutic agent is a siRNA which is therapeutically effective against the cancer.
• the present invention provides a 6,7-dihydroxy coumarin phosphonium amphiphile or pharmaceutically acceptable salt thereof for use in the treatment or diagnosis of cancer.
• the cancer is breast cancer.
• the 6,7-dihydroxy coumarin phosphonium amphiphile for use in the treatment or diagnosis of cancer can be a compound of Formula I:
• Z is a negatively charged agent or a negatively charged counterion selected from a halide, mesylate, tosylate, citrate, tartrate, malate, acetate and trifluoroacetate;
• R is hydrogen, a substituted alkyl, a substituted aryl or a substituted heteroatom
• Ri is an aryl, a cycloalkyl or a heteroaryl
• X is a Ci to C30 carbon chain including one or more double or triple bonds, unsubstituted or substituted with alkyl, alkenyl or alkynyl side chains, or -(CH 2 )p-R2-(CH 2 )n-, or -(CH 2 ) 2 -R 2 -(CH 2 ) 2 -R 2 -(CH 2 )m-; wherein, p is 2 or 3, n is an integer from 3 to 6, and m is an integer from 2 to 4; and
• 3 ⁇ 4 is O, NH or S.
• the 6,7-dihydroxy coumarin phosphonium amphiphile for use in the treatment or diagnosis of cancer can be a triphenylphosphonium cation covalently coupled to a 6,7-dihydroxy coumarin moiety. More specifically, the 6,7-dihydroxy coumarin phosphonium amphiphile is a compound of formula II: wherein,
• X is a Ci to C30 carbon chain, preferably a Ce to C10 carbon chain
• Z is a negatively charged agent or a negatively charged counterion selected from a halide, mesylate, tosylate, citrate, tartrate, malate, acetate and trifluoroacetate;
• R is hydrogen, a substituted alkyl, a substituted aryl, or a substituted heteroatom.
• R is hydrogen.
• X is a Cl to C30 carbon chain including one or more double or triple bonds, unsubstituted or substituted with alkyl, alkenyl or alkynyl side chains.
• X is an octylene group.
• the negatively charged agent may be a therapeutic agent or a diagnostic agent.
• Z is a bromide anion.
• Z is a negatively charged therapeutic agent, for example, a siRNA, suitable to target the cancer being treated.
• the cancer is breast cancer.
• the 6,7-dihydroxy coumarin phosphonium amphiphile for use in the treatment of cancer is Mito-Esc of the formula III: Formula III
• Z is a negatively charged agent or a negatively charged counterion selected from a halide, mesylate, tosylate, citrate, tartrate, malate, acetate and trifluoroacetate.
• the present invention provides a method of treating or diagnosing cancer, for example, breast cancer, cervical cancer, lung cancer and liver cancer. More particularly, a method of treating breast cancer such as triple -negative breast cancer and ER+ve breast cancer, said method comprising administering an effective amount of a compound of formula I to a patient in need thereof, wherein said compound is a compound of formula II: wherein,
• X is a Ci to C30 carbon chain, preferably a Ce to C10 carbon chain
• Z is a negatively charged therapeutic agent or a negatively charged counterion selected from a halide, mesylate, tosylate, citrate, tartrate, malate, acetate and trifluoroacetate;
• R is hydrogen, a substituted alkyl, a substituted aryl or a substituted heteroatom.
• R is hydrogen.
• X is a Cl to C30 carbon chain including one or more double or triple bonds, unsubstituted or substituted with alkyl, alkenyl or alkynyl side chains.
• X is an octylene group.
• Z is a bromide anion.
• Z is a negatively charged therapeutic agent, for example, siRNA suitable to target the cancer being treated.
• the cancer is breast cancer.
• the compound of Formula I or Formula II is Mito-Esc of the formula III: Formula III wherein Z is a negatively charged agent or a halide.
• the present disclosure relates to a complex of 6,7-dihydroxy coumarin phosphonium amphiphile and a negatively charged agent.
• the present disclosure relates to a nanoparticle comprising a complex of 6,7-dihydroxy coumarin phosphonium amphiphile and a negatively charged agent.
• the 6,7-dihydroxy coumarin phosphonium amphiphile is a compound of Formula IV:
• R is hydrogen, a substituted alkyl, a substituted aryl or a substituted heteroatom
• Ri is an aryl, a cycloalkyl or a heteroaryl
• X is a Ci to C30 carbon chain including one or more double or triple bonds, unsubstituted or substituted with alkyl, alkenyl or alkynyl side chains, or
• the 6,7-dihydroxy coumarin phosphonium amphiphile is a triphenylphosphonium cation covalently coupled 6,7-dihydroxy coumarin moiety of Formula V : wherein,
• R is hydrogen, a substituted alkyl, a substituted aryl or a substituted heteroatom
• Ri is an aryl, a cycloalkyl or a heteroaryl
• X is a Ci to C30 carbon chain including one or more double or triple bonds, unsubstituted or substituted with alkyl, alkenyl or alkynyl side chains, or
• the 6,7-dihydroxy coumarin phosphonium amphiphile is octyl tagged esculetin (Mito-Esculetin / Mito-Esc) of Formula VI: Formula VI.
• the complex of 6,7-dihydroxy coumarin phosphonium amphiphile and a negatively charged agent is represented by a compound of Formula I: wherein, Z is a negatively charged agent or a negatively charged counterion selected from mesylate, tosylate, citrate, tartrate, malate, acetate and trifluoroacetate;
• R is hydrogen, a substituted alkyl, a substituted aryl or a substituted heteroatom
• Ri is an aryl, a cycloalkyl or a heteroaryl
• X is a Ci to C30 carbon chain including one or more double or triple bonds, unsubstituted or substituted with alkyl, alkenyl or alkynyl side chains, or
• the complex of 6,7-dihydroxy coumarin phosphonium amphiphile and a negatively charged agent is represented by a compound of Formula II: wherein,
• X is a Ci to C30 carbon chain, preferably a Ce to C10 carbon chain
• Z is a negatively charged agent or a negatively charged counterion selected from mesylate, tosylate, citrate, tartrate, malate, acetate and trifluoroacetate;
• R is hydrogen, one or more substituted alkyl, one or more substituted aryl or one or more substituted heteroatom.
• R is hydrogen.
• the complex of 6,7-dihydroxy coumarin phosphonium amphiphile and a negatively charged agent is represented by a compound of Formula III: Formula III wherein,
• Z is a negatively charged agent or a negatively charged counterion selected from mesylate, tosylate, citrate, tartrate, malate, acetate and trifluoroacetate.
• Z is a negatively charged agent selected from a therapeutic agent, a diagnostic agent and a nucleic acid.
• the negatively charged agent can be a nucleic acid, for example, a plasmid DNAs, antisense oligonucleotides, small interfering RNAs (siRNAs), small hairpin RNAs (shRNAs), microRNA and messenger RNA (mRNA).
• siRNAs small interfering RNAs
• shRNAs small hairpin RNAs
• mRNA messenger RNA
• the negatively charged agent may be a therapeutic agent or a diagnostic agent.
• the therapeutic agent is intended for delivery to the cytoplasm of a target cell, thereby exerting its intended therapeutic effect within the cytoplasm of the target cell.
• the therapeutic agent will be negatively charged anti-cancer agents, a siRNA or mRNA.
• the siRNA may be effective for the treatment or diagnosis of any disease or disorder, for example, the treatment or diagnosis of cancer, peripheral nerve disease, acute hepatic porphyria and others.
• the siRNA can be used to treat breast cancer, cervical cancer, lung cancer and liver cancer. More particularly, breast cancers such as triple-negative breast cancer and ER+ve breast cancer.
• the therapeutic agent can be an RNA vaccine, for example, an RNA vaccine against a virus, for example, coronavirus.
• the agent is a siRNA.
• the siRNA can be targeted at treating or diagnosing any specific disease or disorder.
• the siRNA can be effective at targeting cancer to trigger their specific cell death and / or to prevent cell growth and division of such cells.
• the siRNA can be specifically targeted to breast cancer cells.
• the complex of 6,7-dihydroxy coumarin phosphonium amphiphile and a negatively charged agent is a complex of Mito-Esc and siRNA, wherein Mito-Esc is represented by a compound of Formula VI: Formula VI.
• the nanoparticle comprising complex of 6,7- dihydroxy coumarin phosphonium amphiphile and a negatively charged agent is a nanoparticle comprising a complex of Mito-Esc and siRNA, wherein Mito-Esc is represented by a compound of Formula VI: Formula VI.
• the complex or nanoparticle of the present disclosure is useful in the treatment or diagnosis of cancer.
• the complex or nanoparticle of the present disclosure is useful in the treatment or diagnosis of cancer.
• the present disclosure further provides a pharmaceutical composition comprising a nanoparticle or a complex according to the aspects of present disclosure.
• the present disclosure also provides a method of treating or ameliorating the progression of cancer, wherein said method comprises administration of a pharmaceutical composition comprising the nanoparticle or the complex of 6,7-dihydroxy coumarin phosphonium amphiphile and negatively charged therapeutic agent to the patient.
• the pharmaceutical composition is formulated for oral or parenteral administration.
• the pharmaceutical composition is administered as an oral dosage form.
• the oral dosage form is in the form of tablet, capsule, dispersible tablets, sachets, sprinkles, liquids, solution, suspension, emulsion and the like. If the oral dosage form is a tablet, the tablet can be of any suitable shape such as round, spherical, or oval.
• the tablet may have a monolithic or a multi-layered structure.
• the pharmaceutical composition of the present invention can be obtained by conventional approaches using conventional pharmaceutically acceptable excipients well known in the art.
• pharmaceutically acceptable excipients suitable for tablet preparation include, but not limited to, diluents (e.g., calcium phosphate- dibasic, calcium carbonate, lactose, glucose, microcrystalline cellulose, cellulose powdered, silicified microcrystalline cellulose, calcium silicate, starch, starch pregelatinized, or polyols such as mannitol, sorbitol, xylitol, maltitol, and sucrose), binders (e.g., starch, pregelatinized starch, carboxymethyl cellulose, sodium cellulose, microcrystalline cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, crospovidone, or combinations thereof), disintegrants (e.g., cross-linked dil
• the parenteral administration can be formulated as a solution, suspension, emulsion, particle, powder, or lyophilized powder in association, or separately provided, with a pharmaceutically acceptable parenteral vehicle.
• a pharmaceutically acceptable parenteral vehicle examples include water, saline, Ringer's solution, dextrose solution, and about 1- 10% human serum albumin. Liposomes and non-aqueous vehicles, such as fixed oils, can also be used.
• the vehicle or lyophilized powder can contain additives that maintain isotonicity (e.g., sodium chloride, mannitol) and chemical stability (e.g., buffers and preservatives).
• the formulation is sterilized by known or suitable techniques.
• parenteral formulation may comprise a common excipient that includes, but not limited to, sterile water or saline, polyalkylene glycols, such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes and the like.
• Aqueous or oily suspensions for injection can be prepared by using an appropriate emulsifier or humidifier and a suspending agent, according to known methods.
• Parenteral route of administration includes, but not limited to subcutaneous route, intramuscular route, intravenous route, intrathecal route or intraperitoneal.
• formulations of the present invention can be prepared by a process known or otherwise described in the prior art, for example the process disclosed in Remington's Pharmaceutical Sciences.
• the present invention further provides a method of delivering a negatively charged agent, wherein said agent is complexed to a 6,7-dihydroxy coumarin phosphonium amphiphile.
• the complex of the agent and 6,7-dihydroxy coumarin phosphonium amphiphile is in the form of a nanoparticle, as described above.
• the negatively charged agent may be a therapeutic agent or a diagnostic agent.
• the present invention provides a method of delivering a negatively charged therapeutic agent, wherein said agent is complexed to a 6,7-dihydroxy coumarin phosphonium amphiphile. More preferably, the complex of the therapeutic agent and 6,7-dihydroxy coumarin phosphonium amphiphile is in the form of a nanoparticle.
• the present invention further provides a method of intracellular delivery of a negatively charged agent, said method comprising administering an effective amount of said agent complexed to a 6,7-dihydroxy coumarin phosphonium amphiphile.
• the complex of the agent and 6,7-dihydroxy coumarin phosphonium amphiphile is in the form of a nanoparticle, as described above.
• the negatively charged agent may be a therapeutic agent or a diagnostic agent.
• the invention provides a method of intracellular delivery of a negatively charged therapeutic agent, said method comprising administering an effective amount of said therapeutic agent complexed to a 6,7-dihydroxy coumarin phosphonium amphiphile. More preferably, the complex is in the form of a nanoparticle.
• Example 1 Synthesis of Compounds Synthesis of Mito-Esculetin and control TPP molecules was carried according to the following synthetic protocols.
• Trifluoromethanesulfonic anhydride (4.3 mL, 1.3 equiv) was added dropwise over 10 min. to a mixture of 3 (4 g, 1 eq.) and triethylamine (3.5 mL, 1.3 equiv) in dry dichloromethane (30 mL) at 0 °C. Then the mixture was stirred for 12 h at room temperature. After that, the mixture was diluted with 50% etherhexane and filtered through a short pad of silica, the filtrate was concentrated to a residue, which was purified by flash chromatography to give the corresponding product 4 (4.6 g, 70%).
• MDA-MB-231 (a Triple negative breast cancer cell line, ATCC) and MCF-IOA cells (normal mammary epithelial cells, ATCC) were grown in Dulbecco's Modified Eagle's medium (DMEM) containing 10% FBS, 1% (v/v) Sodium Pyruvate (100 mM), Sodium bicarbonate (26 mM), L-glutamine (4 mM), penicillin (100 units/ml), and streptomycin (100 qg/ml). Cells were maintained in an incubator at 37 °C in a humidified atmosphere of 5% CO2 and 95% air.
• DMEM Dulbecco's Modified Eagle's medium
• FESEM Field emission scanning electron microscopic
• the size (hydrodynamic diameter) and the surface charge (zeta potentials) of a Mito-Esc nanoparticle were measured by photon correlation spectroscopy and the electrophoretic mobility on aZetasizer 3000HSA (Malvern, UK).
• the size was measured in deionized water with a sample refractive index of 1.33, a viscosity of 0.88 cP and a temperature of 25 °C.
• the size was measured in triplicate.
• the zeta potential was measured using the following parameters: viscosity, 0.88 cP; dielectric constant, 78.5, and temperature, 25 °C.
• siRNA lipoplexes were prepared by complexing siRNA with Mito-Esc, Mito-isoscopoletin and octyl TPP cation at described P + /P ratios. The samples were incubated for 30 min at room temperature prior to addition into a well. The siRNA bands were visualized under UV illumination at 365 nm.
• a trypan blue dye exclusion assay was used. Briefly, cells were seeded in a 12-well plate at a density of 3xl0 4 cells per well and cultured overnight before transfection. Medium was replaced with 0.5 mL fresh serum free DMEM. siMnSOD (40 nM) was complexed either with lipofectamine-2000 for control or with 2.5 mM Mito-Esc in serum free DMEM medium for 30 min before addition into the plates.
• the cells were incubated for 48 h, and at the end of the experiments, cells were trypsinized, spun at 800g for 2 min and resuspended in 1 mL fresh medium.
• the cell suspension (10 m ⁇ ) was mixed with an equal amount of trypan blue and counted using an automated cell counter (Countess, Life Technologies).
• cell pellets were lysed in a RIPA buffer containing protease inhibitor cocktail, phosphatase inhibitor cocktail -2, 3. Proteins were resolved by SDS- PAGE and blotted onto a nitrocellulose membrane and blocked with 5% bovine serum albumin, washed, and incubated with primary antibodies (1: 1000) over night at 4 °C. The membranes were then washed and incubated for 1 h with anti-rabbit/mouse IgG horseradish peroxidase linked secondary antibodies (1 :5000). ECL reagent (Amersham GE) was applied on the membrane prior to developing with a chemiluminescent system (Bio-Rad).
• florescent siRNA or siMnSOD 40 nM was complexed either with lipofectamine-2000, as a positive control or with Mito-Esc (2.5 mM) in serum free DMEM medium for 30 min before addition into the plates. After incubation of the cells with siRNA complexes for 6 h, the medium was removed and replaced with 1 mL fresh DMEM medium containing 10% FBS and the cells were further incubated for 24 h.
• MDA-MB-231 cells were seeded on a coverslip in 12-well plates at a density of 3 x 10 4 cells per well in 1 mL complete DMEM and cultured for 12 h.
• Fluorescent (Cy-5) siRNA was complexed either with lipofectamine-2000 (positive control) or with Mito-Esc (2.5 pM) or parent esculetin (2.5 pM) or with different cationic lipids in serum free DMEM medium for 30 min before addition into the plates. These lipoplexes were added to the cells and incubated for 6 h. After that, cells were washed twice with PBS and fixed with 4% paraformaldehyde for 15 min.
• MDA-MB-231 breast cancer cells and MCF-IOA normal mammary epithelial cells
• Mito-Esc significantly caused a dose-dependent cell death of MDA-MB-231 cells from 1.5-7.5 pM
• parent esculetin (Esc) induced cytotoxicity from 50 pM ( Figure 1A and IB).
• Mito-Esc did not show any noticeable toxicity in normal mammary epithelial cells like MCF-IOA cells at any of the indicated concentrations (5-50 pM) ( Figure 1C). Thereby showing that Mito-Esc induces anti -proliferative effects preferentially in cancer cells. It was found that Mito-Esc accumulates significantly more in the mitochondrial fraction of MDA-MB-231 breast cancer cells, in comparison to MCF-IOA cells. Increased accumulation of Mito-Esc in breast cancer cells induced enhanced mitochondrial superoxide production that in turn depolarized the mitochondrial membrane potential leading to breast cancer cell death.
• Mito-Esc accumulates more in cancer cells, in comparison to normal cells, thus preferentially causing cancer cell death at significantly lower concentrations.
• Example 3 Effects of Mito-Esc on viability in different cancer cell lines:
• Cytotoxicity of Mito-Esc on different cancer cell lines HeLa (cervical), HepG2 (liver), MCF-7 (ER+ve breast), A549 (lung), DU-145 (prostate) cancer cells and MCF-IOA (normal mammary epithelial cells) were determined by treating with Mito-Esc (0.5-100 mM) for 24 h and cell viability was measured by Sulforhodamine B assay.
• Mito-Esc significantly caused a dose-dependent cell death of HeLa (cervical), HepG2 (liver), MCF-7 (ER+ve breast), A549 (lung) cells, as shown in Table 1, it did not show any noticeable toxicity in normal mammary epithelial cells like MCF-IOA cells. Thereby showing that Mito-Esc induces anti-proliferative effects preferentially in cancer cells.
• Example 5 In-vivo orthotopic tumor model:
• Mito-Esc nanoparticle solutions were prepared at various concentrations according to the desired final P+:P- charge ratio. Twenty pL solution of the Mito-Esc/siRNA complex was prepared to maintain a constant amount of siRNA in each solution (1 pg in 10 pL), and varying the amount of Mito-Esc according to the P+:P- charge ratio. The prepared mixtures were gently vortexed for 5 min. and incubated for 30 min at room temperature for complex formation. Complexing 1 pg of siRNA with 2, 4, 6, 8, 10, 12, 14 pg of Mito-Esc resulted in 1: 1, 2:1, 3: 1, 4:1, 5: 1, 6: 1, 7: 1 P+:P- charge ratios respectively.
• Mito-Esc The efficiency of Mito-Esc to bind siRNA was checked by agarose gel electrophoresis. Also, in order to assess the importance of hydrogen bonding in forming the stable siRNA complexes, Mito-isoscopoletin was synthesized by protecting the dihydroxy group with methyl group. Octyl TPP cation was used as a negative control.
• MDA-MB-231 cells were treated with the lipoplex for 6 h in an Opti-MEM medium containing reduced serum ( ⁇ 2%) after which, media was replaced by serum containing medium (10% serum) for another 48 h and measured the cell viability by trypan blue dye exclusion method.
• siMnSOD was also complexed with lipofectamine-2000 (positive control). It was found that Mito-Esc complexed with siMnSOD induced 94% cell death in MDA-MB-231 cells, while Lipofectamine-2000 and siMnSOD complex induced 66% cell death (Figure 3A).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Genetics & Genomics (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Biochemistry (AREA)
• Biotechnology (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Zoology (AREA)
• General Engineering & Computer Science (AREA)
• Wood Science & Technology (AREA)
• Biophysics (AREA)
• Microbiology (AREA)
• Plant Pathology (AREA)
• Physics & Mathematics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Oscillators With Electromechanical Resonators (AREA)
• Medicinal Preparation (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=82558096

Family Applications (1)

Country Status (8)

Cited By (1)

Families Citing this family (1)

Citations (3)

• 2022
  • 2022-06-03 AU AU2022287326A patent/AU2022287326A1/en active Pending
  • 2022-06-03 JP JP2023574125A patent/JP2024521209A/ja active Pending
  • 2022-06-03 CA CA3220535A patent/CA3220535A1/en active Pending
  • 2022-06-03 WO PCT/IB2022/055214 patent/WO2022254405A1/en not_active Ceased
  • 2022-06-03 EP EP22741839.9A patent/EP4346902A1/en active Pending
  • 2022-06-03 US US18/562,733 patent/US20240277851A1/en active Pending
  • 2022-06-03 BR BR112023025242A patent/BR112023025242A2/pt unknown
  • 2022-06-03 CN CN202280036975.2A patent/CN117396227A/zh active Pending

Patent Citations (4)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events